Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Phase 1/2 × Has announcements × Tumor-Agnostic × Clear all

Phase

Phase 3 2 Phase 1/2 2 Phase 1 1

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11 Thoracic 9 Other hematologic neoplasm 9 Gastrointestinal 8 CNS 7 Head & Neck 6 Endocrine 5 Sarcoma 4 Myeloid 4 Genitourinary 3 Breast 3 Tumor-Agnostic 2 Plasma cell 2 Other solid neoplasm 2 NET 2 Gynecologic 1

Conditions

Interventions

pembrolizumab 1 lenvatinib 1 larotrectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02637687 2025-06-22

SCOUT

Bayer

Phase 1/2 Active not recruiting

154 enrolled 3 FDA

Neoplasms

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡